A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

The company’s FDA-approved first generic sertraline capsules secured a 180‑day exclusivity period, highlighting strategic generic development pathways.

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

Evolving trade policies and tariffs strain bio/pharmaceutical manufacturers, affecting profits and operational strategies.

The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse ...

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava ...

FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.